Evidence
J Addict Dis. 2024 Feb 24:1-8. doi: 10.1080/10550887.2024.2315366. Online ahead of print.
ABSTRACT
BACKGROUND: There has been extensive research demonstrating the effectiveness of medications for opioid use disorder (MOUD) but limited investigation into its long-term retention rate.
OBJECTIVE: Assess the long-term treatment retention of a buprenorphine-based MOUD clinic with additional stratifications by age and gender.
METHODS: This retrospective study analyzed 10-years of data from a MOUD clinic in West Virginia that served 3,255 unique patients during the study period (2009-2019). Retention was measured by summation of total treatment days with a new episode of care defined as re-initiating buprenorphine treatment after 60+ consecutive days of nonattendance. Kaplan-Meier survival analysis, with the log-rank test, was used to compare retention by gender and age.
RESULTS: The mean age was 38 (SD = 10.6) and 95% were non-Hispanic white. Irrespective of treatment episode, 56.8% of patients were retained ≥ 90 days, and the overall median time in treatment was 112 days. Considering only the first treatment episode, 48.4% of 3,255 patients were retained at least 90 days and the overall median was 77 days. Female patients had a ≥ 90 day retention rate of 52.2% for the first admission and 60.1% for multiple admissions, both significantly higher than those of male subjects (44.1% and 53.0%). Additionally, patients ≤ 24 years old had the lowest rate of treatment retention, while patients aged ≥ 35 had the highest.
CONCLUSIONS: This study adds to the limited data regarding long-term retention in MOUD. Our findings indicate gender and age were highly correlated with retention in MOUD treatment.
PMID:38400724 | DOI:10.1080/10550887.2024.2315366
Add to Google Keep
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
10-year retention of a comprehensive treatment model of buprenorphine for opioid use disorder
🌐 90 Days
VR Related Evidence Matrix
- Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes
- Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults
- Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality
- Stepped Care for Patients to Optimize Whole Recovery (SC-POWR): An Effectiveness Trial Evaluating a Stepped Care Model for Individuals With Opioid Use Disorder and Chronic Pain
- Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives
- Efficacy of Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT) in Individuals With Chronic Pain and Opioid Use Disorder: Protocol for a Randomized Clinical Trial of a Digital Cognitive Behavioral Treatment
- Characterizing Acute and Postsurgical Pain Management in Patients Receiving Buprenorphine or Buprenorphine/naloxone
- An Australian retrospective observational cohort comparison of the use of long-acting injectable buprenorphine products
- The influence of familial networks and stigma on prison-based medication initiation for individuals with opioid use disorder: Clinicians' perceptions
- Licensure Policies May Help States Ensure Access To Opioid Use Disorder Medication In Specialty Addiction Treatment
- Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency
- Exemplar Hospital initiation trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098B a randomized implementation study to support hospitals in caring for patients with opioid use disorder
- Federal Impacts on Buprenorphine Prescribing in Washington State, 2012 to 2022
- Effect of a Co-Located Bridging Recovery Initiative on Hospital Length of Stay Among Patients With Opioid Use Disorder: The BRIDGE Randomized Clinical Trial
- Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing: A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial
- Healthcare staff's perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study
- Characterization of peer support services for substance use disorders in 11 US emergency departments in 2020: findings from a NIDA clinical trials network site selection process
- Blood pressure response to extended-release naltrexone in heroin and prescription opioid users and its implications for cardiovascular morbidity
- Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada
- Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study
- Cognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine
- Experiences of Stigma and Discrimination Compounded by Intersecting Identities among Individuals Receiving Medication for Opioid Use Disorder
- Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial
- Multimodal Acute Pain Management in the Parturient with Opioid Use Disorder: A Review
- Assessing men with opioid use disorder for testosterone deficiency after the development of symptoms
- Medication-based treatment among rural, primary care patients diagnosed with opioid use disorder and alcohol use disorder
- Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study)
- Guanfacine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Down Syndrome: A Retrospective Chart Review
- Access to Mental Health and Substance Use Treatment in Comprehensive Primary Care Plus
- A pilot randomized controlled trial of medication adherence therapy: Psychosocial leverage using a significant other (MAT-PLUS) for individuals on extended-release naltrexone
- Relationship-Oriented Recovery System for Youth (RORSY): Clinical Protocol for Transition-Age Youth with Opioid Use Disorders
- Relationship-Oriented Recovery System for Youth (RORSY): Clinical Protocol for Transition-Age Youth with Opioid Use Disorders
- A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy
- Illness-related outcomes of illicit substance use disorder in adolescents with early onset schizophrenia: a multicenter study
- Establishing a research agenda for the study and assessment of opioid withdrawal
- What features of drug treatment programs help, or not, with access? a qualitative study of the perspectives of family members and community-based organization staff in Atlantic Canada
- Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy
- Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy
- Buprenorphine Affects the Initiation and Severity of Interleukin Induced Acute Pancreatitis in Mice
- Comparative costs and potential affordability of a multifaceted intervention to improve treatment outcomes among people with HIV who inject drugs in Russia: economic evaluation of the LINC-II randomized controlled trial
- Tools to implement measurement-based care (MBC) in the treatment of opioid use disorder (OUD): toward a consensus
- The Prevalence of Post-traumatic Stress Disorder as Part of Post-ICU Syndrome among Israeli ICU Survivors
- Examining Profiles and Treatment Outcomes in Dual Diagnosis: Comparison of Coordinated Treatment With Mental Health Services Versus Addiction Center Alone: A Real-World Data Analysis
- Withdrawal catastrophizing scale: initial psychometric properties and implications for the study of opioid use disorder and hyperkatifeia
- Substance use patterns, sociodemographics, and health profiles of harm reduction service recipients in Burlington, Vermont
- The Dropout Rates and Associated Factors in Patients with Mood Disorders in Long-term Naturalistic Treatment
- Association between electroconvulsive therapy and time to readmission after a manic episode
- The association of pain impact and sleep disruption with opioid withdrawal during opioid-use disorder treatment
- Short- and long-term safety of discontinuing chronic opioid therapy among older adults with Alzheimer's disease and related dementia
- Long-Term Cardiovascular Risk Associated With Treatment of Attention-Deficit/Hyperactivity Disorder in Adults
- Short-term effects of semaglutide among patients with obesity with and without food addiction: an observational study
- Over 30 years of STEP: The Pittsburgh experience with first-episode psychosis
- Over 30 years of STEP: The Pittsburgh experience with first-episode psychosis
- Patient adherence as a predictor of acute and long-term outcomes in concentrated exposure treatment for difficult-to-treat obsessive-compulsive disorder
- Patient adherence as a predictor of acute and long-term outcomes in concentrated exposure treatment for difficult-to-treat obsessive-compulsive disorder
- A nationwide cohort study on the association between intensive care treatments and mental distress linked psychiatric disorders
- Postoperative urinary retention (POUR): A narrative review
- Postoperative urinary retention (POUR): A narrative review
- Addiction Medicine Treatment Utilization by Race/Ethnicity Among Adolescents With Substance Use Problems Before Versus During the COVID-19 Pandemic
- Prescription opioid dispensing patterns among patients with schizophrenia or bipolar disorder
- Psychotropic Medication Use and Polypharmacy Among Children and Adolescents Initiating Intensive Behavioral Therapy for Severe Challenging Behavior
Evidence Blueprint
10-year retention of a comprehensive treatment model of buprenorphine for opioid use disorder
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
10-year retention of a comprehensive treatment model of buprenorphine for opioid use disorder
🌐 365 Days
VR Related Evidence Matrix
- Social Determinants of Health and Continuity of Medications for Opioid Use Disorder Among Patients Receiving Treatment in Rural Primary Care Settings
- Evaluation of a Primary Care-Based Multidisciplinary Transition Clinic for Patients Newly Initiated on Buprenorphine in the Emergency Department
- Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation
- Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use
- Survey of barriers and opportunities for prescribing buprenorphine for opioid use disorder in Alabama
- Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration
- Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder
- The impact of methamphetamine use on medications for opioid use disorder (MOUD) treatment retention: a scoping review
- Relationship between medication adherence for opioid use disorder and health care costs and health care events in a claims dataset
- Health care use and cost of treatment for adolescents and young adults with opioid use disorder
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- Gender differences in utilization of behavioral therapy and medication for opioid use disorder during the pandemic: A retrospective veteran cohort study
- Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature
- Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study
- Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail
- Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes
- Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults
- Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder
- Hospital-based opioid treatment: Expanding and sustaining the model in Texas
- Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA
- Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder
- Treatment of poppy seed tea misuse with buprenorphine in a telehealth practice: a case series
- The association of medical providers' attitudes about naloxone and people with opioid use disorder and their self-reported "low-barrier" treatment practices
- Association of MOUD ECHO Participation on Expansion of Buprenorphine Prescribing in Rural Primary Care
- Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective
- Buprenorphine/naloxone micro-induction in a tertiary care hospital: a retrospective cohort analysis
- Medications for opioid use disorder associated with reduced readmissions for patients with severe injection-related infections: A matched cohort study
- Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada
- Associations between stimulant use and return to illicit opioid use following initiation onto medication for opioid use disorder
- Ambivalence and contingencies: A qualitative examination of peer recovery coaches' attitudes toward medications for opioid use disorder
- Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives
- Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers
- Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality
- ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids
- Buprenorphine use and setting type among reproductive-aged women self-reporting nonmedical prescription opioid use
- Buprenorphine: two adolescent case reports of bridging the transmucosal form to the extended-release subcutaneous injectable form
- Stepped Care for Patients to Optimize Whole Recovery (SC-POWR): An Effectiveness Trial Evaluating a Stepped Care Model for Individuals With Opioid Use Disorder and Chronic Pain
- Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial
- Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives
- Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone
- Medical and genetic correlates of long-term buprenorphine treatment in the electronic health records
- Opioid-induced hypogonadism in opioid use disorder, its role in negative reinforcement, and implications for treatment and retention
- Predictors of treatment retention and survival among methadone-maintained patients: A possible role for a functional delta opioid receptor gene variant
- Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study
- Severe tianeptine withdrawal symptoms managed with medications for opioid use disorder: a case report
- Homelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT
- An Approach to Enhancing Medication Treatment for Opioid Use Disorder in the HEALing Communities Study
- Medications for Alcohol Use Disorder and Retention in Care in Medicaid-Enrolled Youth, 2014-2019
- Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022
- The role of social connection in opioid use disorder treatment engagement
- Implementation of medication for opioid use disorder treatment in Indian health clinics in California: A qualitative evaluation
- Evidence on Buprenorphine Dose Limits: A Review
- The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose
- It takes a village: A pilot study of a group telehealth intervention for support persons affected by opioid use disorder
- Efficacy of Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT) in Individuals With Chronic Pain and Opioid Use Disorder: Protocol for a Randomized Clinical Trial of a Digital Cognitive Behavioral Treatment
- Referral of patients from rural primary care clinics to telemedicine vendors for opioid use disorder treatment: A mixed-methods study
- Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
- Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals
- Undertreatment of opioid use disorder in patients hospitalized with injection drug use associated infections
- Initiation of Extended-release Depot Buprenorphine in a Patient Subject to a Community Treatment Order for Both Antipsychotic and Opioid Agonist Treatments
- Patient opinion and acceptance of emergency department buprenorphine/naloxone to-go home initiation packs
- Characterizing Acute and Postsurgical Pain Management in Patients Receiving Buprenorphine or Buprenorphine/naloxone
- Hospital-based clinicians lack knowledge and comfort in initiating medications for opioid use disorder: opportunities for training innovation